NASDAQ: APVO | Healthcare / Biotechnology / USA |
0.1994 | +0.0204 | +11.40% | Vol 501.01K | 1Y Perf -94.19% |
Nov 29th, 2023 16:00 DELAYED |
BID | 0.1952 | ASK | 0.2035 | ||
Open | 0.1790 | Previous Close | 0.1790 | ||
Pre-Market | - | After-Market | 0.20 | ||
- - | 0.01 2.71% |
Target Price | 18.00 | Analyst Rating | Strong Buy 1.00 | |
Potential % | 8.93K | Finscreener Ranking | ★★★★★ 68.22 | |
Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★★★★★ 68.59 | |
Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★★★★★ 72.34 | |
Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
Price Range Ratio 52W % | 0.68 | Earnings Rating | Strong Buy | |
Market Cap | 3.51M | Earnings Date | 9th Nov 2023 | |
Alpha | -0.04 | Standard Deviation | 0.78 | |
Beta | 5.24 |
Today's Price Range 0.17900.2089 | 52W Range 0.15177.20 | 5 Year PE Ratio Range -1.2022.70 |
Summary:
Sell
Technical Indicators: | Neutral |
Moving Averages: | Strong Sell |
Performance | |||
---|---|---|---|
1 Week | 4.95% | ||
1 Month | -33.53% | ||
3 Months | -52.18% | ||
6 Months | -87.77% | ||
1 Year | -94.19% | ||
3 Years | -99.54% | ||
5 Years | -91.33% | ||
10 Years | - |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | -52.69 | |||
ROE last 12 Months | 58.32 | |||
ROA (5Y Avg) | -30.41 | |||
ROA last 12 Months | 14.89 | |||
ROC (5Y Avg) | -43.38 | |||
ROC last 12 Months | 25.59 | |||
Return on invested Capital Q | -25.61 | |||
Return on invested Capital Y | -29.86 | |||
Assets Turnover | 0.10 | |||
Receivables Turnover | 2.00 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
1.70 | ||||
0.70 | ||||
3.79 | ||||
- | ||||
-0.70 | ||||
-3.80 | ||||
0.70 | ||||
3.10 | ||||
-902 968.00 | ||||
Forward PE | -0.14 | |||
PEG | - |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
2.80 | ||||
3.20 | ||||
0.34 | ||||
0.64 | ||||
- | ||||
Leverage Ratio | 3.40 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
82.60 | ||||
-368.70 | ||||
-354.00 | ||||
-329.90 | ||||
99.40 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
3.11M | ||||
0.61 | ||||
-28.67 | ||||
-23.90 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q02 2023 | -1.12 | -1.23 | -9.82 |
Q01 2023 | -1.19 | 0.26 | 121.85 |
Q03 2022 | -1.64 | -1.53 | 6.71 |
Q02 2022 | -1.33 | -1.86 | -39.85 |
Q01 2022 | -1.15 | -1.59 | -38.26 |
Q03 2021 | -1.48 | -1.45 | 2.03 |
Q02 2021 | -1.95 | -1.78 | 8.72 |
Q01 2021 | -1.62 | -1.74 | -7.41 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
12/2023 QR | -0.37 | 37.29 | Positive |
12/2023 FY | -1.78 | 21.24 | Positive |
3/2024 QR | -0.36 | 84.81 | Positive |
12/2024 FY | -1.33 | - | - |
Next Report Date | - |
Estimated EPS Next Report | -0.72 |
Estimates Count | 1 |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 501.01K |
Shares Outstanding | 17.62K |
Shares Float | 16.97M |
Trades Count | 918 |
Dollar Volume | 97.92K |
Avg. Volume | 421.87K |
Avg. Weekly Volume | 245.61K |
Avg. Monthly Volume | 551.93K |
Avg. Quarterly Volume | 468.07K |
Aptevo Therapeutics Inc. (NASDAQ: APVO) stock closed at 0.1994 per share at the end of the most recent trading day (a 11.4% change compared to the prior day closing price) with a volume of 501.01K shares and market capitalization of 3.51M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 80 people. Aptevo Therapeutics Inc. CEO is Marvin L. White.
The one-year performance of Aptevo Therapeutics Inc. stock is -94.19%, while year-to-date (YTD) performance is -91.41%. APVO stock has a five-year performance of -91.33%. Its 52-week range is between 0.1517 and 7.2, which gives APVO stock a 52-week price range ratio of 0.68%
Aptevo Therapeutics Inc. currently has a PE ratio of 1.70, a price-to-book (PB) ratio of 0.70, a price-to-sale (PS) ratio of 3.79, a price to cashflow ratio of -, a PEG ratio of -, a ROA of 14.89%, a ROC of 25.59% and a ROE of 58.32%. The company’s profit margin is 99.40%, its EBITDA margin is -354.00%, and its revenue ttm is $3.11 Million , which makes it $0.61 revenue per share.
Of the last four earnings reports from Aptevo Therapeutics Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.72 for the next earnings report. Aptevo Therapeutics Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Aptevo Therapeutics Inc. is Strong Buy (1), with a target price of $18, which is +8 927.08% compared to the current price. The earnings rating for Aptevo Therapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Aptevo Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Aptevo Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 11.38, ATR14 : 0.03, CCI20 : -39.14, Chaikin Money Flow : -0.06, MACD : -0.03, Money Flow Index : 50.97, ROC : -14.42, RSI : 39.38, STOCH (14,3) : 43.92, STOCH RSI : 1.00, UO : 47.30, Williams %R : -56.08), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Aptevo Therapeutics Inc. in the last 12-months were: Daphne L. Taylor (Option Excercise at a value of $0), Grant Grady (Sold 0 shares of value $0 ), Jeffrey G. Lamothe (Option Excercise at a value of $0), Kunz Barbara (Sold 0 shares of value $0 ), Kwon Soyoung (Sold 0 shares of value $0 ), Lamothe Jeffrey (Sold 0 shares of value $0 ), Marvin L. White (Option Excercise at a value of $0), Niederhuber John (Sold 0 shares of value $0 ), So Young Kwon (Option Excercise at a value of $0)
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Strong Buy | Strong Buy | Strong Buy |
Aptevo Therapeutics Inc is a biosciences company. The company is engaged in the discovery, development, commercialization and sale of novel oncology and hematology therapeutics. Its pipeline product includes Otlertuzumab, APVO414, Multiple ADAPTIR Candidates, ALG.APV-527, APVO436 and APVO210.
CEO: Marvin L. White
Telephone: +1 206 838-0500
Address: 2401 4th Avenue, Seattle 98121, WA, US
Number of employees: 80
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Copyright © 2023. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer.
General partner of Finscreener is SLOVAKODATA, a.s.
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.